MoonLake Immunotherapeutics (MLTX) Change in Acquisitions & Divestments (2022 - 2026)

MoonLake Immunotherapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $59.2 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 59.15% year-over-year to $59.2 million; the TTM figure through Mar 2026 stood at $382.7 million (up 65.75% YoY), while the FY2025 annual figure was $468.4 million, up 222.58% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $59.2 million, up from $29.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $205.9 million in Q2 2025, with the low at -$1.3 million in Q2 2024.
• The 5-year median for Change in Acquisitions & Divestments is $44.2 million (2024), against an average of $59.5 million.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments slumped 110.26% in 2024, then jumped 15927.29% in 2025.
• MoonLake Immunotherapeutics' Change in Acquisitions & Divestments stood at $9.9 million in 2022, then jumped by 1083.17% to $117.2 million in 2023, then slumped by 100.18% to -$211000.0 in 2024, then jumped by 13965.4% to $29.3 million in 2025, then jumped by 102.24% to $59.2 million in 2026.
• Business Quant data shows MLTX's Change in Acquisitions & Divestments at $59.2 million in Q1 2026, $29.3 million in Q4 2025, and $88.4 million in Q3 2025.